固形腫瘍治療薬の世界市場2016-2020

◆英語タイトル:Global Solid Tumors Drugs Market 2016-2020
◆商品コード:IRTNTR9801
◆発行会社(調査会社):Technavio
◆発行日:2016年6月24日
◆ページ数:156
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single User(1名利用)USD2,500 ⇒換算¥285,000見積依頼/購入/質問フォーム
Five User(~5名利用)USD3,000 ⇒換算¥342,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD4,000 ⇒換算¥456,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご確認ください。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。Technavio社の概要及び新刊レポートはこちらでご確認いただけます。
当調査レポートでは、固形腫瘍治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、固形腫瘍治療薬の世界市場規模及び予測、種類別分析、市場シェア、地域別分析/市場規模、市場の成長要因、市場の課題、コスト分析、市場動向、競争状況などの情報をお届けいたします。
【レポートの概要】

About the Solid Tumors Drugs Market
The rising prevalence of various cancers, which has led to innovations and technological advancements, drives the development of new immunotherapy drugs that are more effective than the available drugs to treat solid tumors.
Solid tumors are an abnormal mass of tissue that do not contain cysts or liquid areas. These may be malignant (cancerous) or benign (not cancerous). They affect bones, organs, and muscles. Based on the type of the cells, solid tumors can be carcinomas, sarcomas, and lymphomas.

Technavio’s analysts forecast the global solid tumors drugs market to grow at a CAGR of 8.6% during the period 2016-2020.

[Covered in this report]
The report covers the present scenario and the growth prospects of the global solid tumors drugs market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded drugs, generics, and biosimilars used to treat solid tumors. It also considers the revenues to be generated from the sales of drugs that are anticipated to be launched into the market along with the decline in revenues from the patent expiries of the branded drugs during the forecast period.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio’s report, Global Solid Tumors Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• F. Hoffmann-La Roche
• Novartis
• Celgene
• Johnson & Johnson
• Pfizer
• BMS

[Other prominent vendors]
• AbbVie
• AbGenomics
• ADC Therapeutics
• Advantagene
• Agensys
• Almac Group
• Ambrx
• Argos Therapeutics
• Array BioPharma
• Astellas Pharma
• AstraZeneca
• Bayer
• Biogen
• Biotech Pharmaceutical
• Boehringer Ingelheim
• Boston Biomedical
• Celldex Therapeutics
• Chugai Pharmaceutical
• Cold Genesys
• CTI BioPharma
• Daiichi Sankyo
• DNAtrix
• Ds-Pharma
• Eleison Pharmaceuticals
• Eli Lilly
• Endo Pharmaceuticals
• Formation Biologics
• Fortress Biotech
• Genmab
• GSK
• Immatics Biotechnologies
• Immunogen
• Immunomedics
• Intas Pharmaceuticals
• Kairos Therapeutics
• Kyowa Hakko Kirin
• MedImmune
• Merck
• Mersana Therapeutics
• Morphotek
• Neovii Biotech
• NewLink Genetics
• Northwest Biotherapeutics
• Novartis
• OncoMed Pharmaceuticals
• Oxford Biotherapeutics
• Peregrine Pharmaceuticals
• Polaris Pharmaceuticals
• Sanofi
• Seattle Genetics
• Spectrum Pharmaceuticals
• Stemcentrx
• Synthon Biopharmaceuticals
• TG Therapeutics
• XBiotech

[Market driver]
• Exposure to risk factors
• For a full, detailed list, view our report

[Market challenge]
• Patent expiration of top-selling drugs
• For a full, detailed list, view our report

[Market trend]
• Emergence of targeted and combination therapies
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

※You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

【レポートの目次】

PART 01: Executive summary
• Highlights

PART 02: Scope of the report
• Market overview
• Assumptions
• Top-vendor offerings

PART 03: Market research methodology
• Research methodology
• Economic indicators

PART 04: Introduction
• Key market highlights
• Markers used for diagnosis of solid tumors

PART 05: Cost analysis

PART 06: Pipeline portfolio
• Anticipated number of products with single and multiple indications by 2020

PART 07: Market landscape
• Market overview
• Market size and forecast
• Five forces analysis

PART 08: Market segmentation by molecule type
• Small molecules
• Biologics

PART 09: Market segmentation by type of therapy
• Chemotherapy
• Hormone therapy
• Targeted therapy
• Immunotherapy

PART 10: Market segmentation by disease
• Global breast cancer drugs market
• Global NHL drugs market
• Global colorectal cancer drugs market
• Global NSCLC drugs market
• Global prostate cancer drugs market
• Global kidney cancer drugs market
• Global retinoblastoma drugs market
• Global cervical cancer market
• Global melanoma drugs market
• Global gastric cancer drugs market
• Global pancreatic cancer drugs market
• Global ovarian cancer drugs market
• Global liver cancer drugs market
• Global HL drugs market
• Global glioblastoma multiforme drugs market

PART 11: Geographical segmentation
• Solid tumors drugs market in Americas
• Solid tumors drugs market in EMEA
• Solid tumors drugs market in APAC

PART 12: Market drivers
• Patient assistance programs
• Exposure to risk factors
• Provision for rare diseases
• Promising pipeline
• Increase in prevalence of solid tumors

PART 13: Impact of drivers

PART 14: Market challenges
• Patent expiration of top-selling drugs
• Poor diagnosis and screening
• High cost of drugs
• Availability of chemotherapy and off-label drugs
• Stringent regulations

PART 15: Impact of drivers and challenges

PART 16: Market trends
• Increase in cancer awareness
• Emergence of targeted and combination therapies
• Emergence of biosimilars
• Joint ventures and partnerships for R&D
• Increase in use of brachytherapy

PART 17: Vendor landscape
• Competitive scenario
• Market share analysis 2015
• F. Hoffmann-La Roche
• Novartis
• Celgene
• Johnson & Johnson
• Pfizer
• BMS
• Other prominent vendors

PART 18: Appendix
• List of abbreviations

PART 19: Explore Technavio

[List of Exhibits]

Exhibit 01: Product offerings
Exhibit 02: Types of solid tumors
Exhibit 03: Markers used for types of solid tumors
Exhibit 04: Annual treatment cost per patient for solid tumor drugs 2014
Exhibit 05: Average cost of surgeries associated with solid tumors 2014 ($)
Exhibit 06: Average cost of chemotherapy 2014 ($)
Exhibit 07: Average cost of radiation therapy 2014 ($)
Exhibit 08: Phase III pipeline molecules for solid tumors
Exhibit 09: Phase II pipeline molecules for solid tumors
Exhibit 10: Phase I pipeline molecules for solid tumors
Exhibit 11: Pre-clinical pipeline molecules for solid tumors
Exhibit 12: Pipeline share of solid tumors drugs 2015
Exhibit 13: Near-launch immuno-oncology pipeline assets 2020
Exhibit 14: Global solid tumors market 2015-2020 ($ billions)
Exhibit 15: Factors influencing global solid tumors drugs market 2015
Exhibit 16: Five forces analysis
Exhibit 17: Segmentation of global solid tumors drugs market by type of molecules 2015
Exhibit 18: Market segmentation by disease
Exhibit 19: Global solid tumors drugs market: Segmentation by disease 2015
Exhibit 20: Global solid tumors drugs market: YoY revenue and growth based on drug class 2015-2020 ($ billions)
Exhibit 21: Stages of breast cancer based on tumor size and extent of metastasis
Exhibit 22: Classification of breast cancer based on genetic makeup of tumor cells
Exhibit 23: Treatment regimen for breast cancer
Exhibit 24: Product offerings for breast cancer drugs market
Exhibit 25: Global breast cancer drugs market 2015-2020 ($ billions)
Exhibit 26: Product offerings for global NHL drugs market
Exhibit 27: Global NHL drugs market 2015-2020 ($ billions)
Exhibit 28: Product offerings for global colorectal cancer drugs market
Exhibit 29: Global colorectal cancer drugs market 2015-2020 ($ billions)
Exhibit 30: Products offerings for global NSCLC drugs market
Exhibit 31: Global NSCLC drugs market 2015-2020 ($ billions)
Exhibit 32: Product offerings for global prostate cancer drugs market
Exhibit 33: Global prostate cancer drugs market 2015-2020 ($ billions)
Exhibit 34: Product offerings for global kidney cancer drugs market
Exhibit 35: Global kidney cancer drugs market 2015-2020 ($ billions)
Exhibit 36: Product offerings for global retinoblastoma drugs market
Exhibit 37: Global retinoblastoma drugs market 2015-2020 ($ billions)
Exhibit 38: Product offerings for global cervical cancer market
Exhibit 39: Global cervical cancer market 2015-2020 ($ billions)
Exhibit 40: Product offerings for global melanoma drugs market
Exhibit 41: Global melanoma drugs market 2015-2020 ($ billions)
Exhibit 42: Products offerings for global gastric cancer drugs market
Exhibit 43: Global gastric cancer drugs market 2015-2020 ($ billions)
Exhibit 44: Products offerings for global pancreatic cancer drugs market
Exhibit 45: Global pancreatic cancer drugs market 2015-2020 ($ billions)
Exhibit 46: Products offerings for global ovarian cancer drugs market
Exhibit 47: Global ovarian cancer drugs market 2015-2020 ($ billions)
Exhibit 48: Product offerings for global liver cancer drugs market
Exhibit 49: Global liver cancer drugs market 2015-2020 ($ billions)
Exhibit 50: Products offerings for global HL drugs market
Exhibit 51: Global HL drugs market 2015-2020 ($ millions)
Exhibit 52: Products offerings for global glioblastoma multiforme drugs market
Exhibit 53: Global glioblastoma multiforme drugs market 2015-2020 ($ millions)
Exhibit 54: Global solid tumors drugs market by geography 2015
Exhibit 55: Global solid tumors drugs market revenue by geography 2015-2020 ($ billions)
Exhibit 56: Global solid tumors drugs market revenue by geography 2015-2020
Exhibit 57: Solid tumors drugs market in Americas 2015-2020 ($ billions)
Exhibit 58: Solid tumors drugs market in EMEA 2015-2020 ($ billions)
Exhibit 59: Solid tumors drugs market in APAC 2015-2020 ($ billions)
Exhibit 60: Global solid tumors drugs market: YoY revenue and growth based on geography 2015-2020 ($ billions)
Exhibit 61: Global incidence of solid tumor types 2015
Exhibit 62: Global mortality of solid tumor types 2015
Exhibit 63: Impact of drivers
Exhibit 64: Patent expiries of major cancer monoclonal antibodies by 2020
Exhibit 65: Average cost comparison of Herceptin 2014
Exhibit 66: Impact of drivers and challenges
Exhibit 67: Expected combination regimen launches in oncology
Exhibit 68: YoY Sales comparison of top drugs 2013-2015 ($ billions)
Exhibit 69: Ranking of major vendors for global solid tumors drugs market
Exhibit 70: Market share analysis of global solid tumors drugs market 2015
Exhibit 71: F. Hoffmann-La Roche: YoY growth and revenue generated from total product sales of MabThera/Rituxan (oncology indications) 2013-2015 ($ billions)
Exhibit 72: MabThera/Rituxan geographic segmentation by revenue 2015
Exhibit 73: F. Hoffmann-La Roche: YoY growth and revenue generated from net product sales of Avastin 2013-2015 ($ billions)
Exhibit 74: F. Hoffmann-La Roche: Geographic segmentation of Avastin by revenue 2015
Exhibit 75: F. Hoffmann-La Roche: YoY growth and revenue generated from net product sales of Herceptin 2013-2015 ($ billions)
Exhibit 76: F. Hoffmann-La Roche: Geographical segmentation of Herceptin 2015
Exhibit 77: F. Hoffmann-La Roche: YoY growth and revenue generated from net product sales of Perjeta 2013-2015 ($ billions)
Exhibit 78: F. Hoffmann-La Roche: Geographical segmentation of Perjeta 2015
Exhibit 79: F. Hoffmann-La Roche: Revenue generated from net product sales of Kadcyla 2013-2015 ($ millions)
Exhibit 80: F. Hoffmann-La Roche: Geographical segmentation of Kadycla 2015
Exhibit 81: F. Hoffmann-La Roche: Revenue generated from net product sales of Tarceva 2013-2015 ($ billions)
Exhibit 82: F. Hoffmann-La Roche: Geographical segmentation of Tarceva 2015
Exhibit 83: F. Hoffmann-La Roche: Key takeaways
Exhibit 84: Novartis: YoY revenue and growth rate of Gleevec 2013-2015 ($ billions)
Exhibit 85: Novartis: YoY revenue and growth rate of Sandostatin 2013-2015 ($ billions)
Exhibit 86: Novartis: YoY revenue and growth rate of Sandostatin 2013-2015 ($ billions)
Exhibit 87: Novartis: Key takeaways
Exhibit 88: Celgene: YoY revenue and growth rate of Revlimid 2013-2015 ($ billions)
Exhibit 89: Celgene: YoY revenue and growth rate of Abraxane 2013-2015 ($ millions)
Exhibit 90: Celgene: YoY revenue and growth rate of Istodax 2013-2015 ($ millions)
Exhibit 91: Celgene: YoY revenue and growth rate of Pomalyst 2013-2015 ($ millions)
Exhibit 92: Celgene: YoY revenue and growth rate of Pomalyst 2013-2015 ($ millions)
Exhibit 93: Celgene: Key takeaways
Exhibit 94: Johnson & Johnson: YoY revenue comparison of Zytiga 2013-2015 ($ billions)
Exhibit 95: Johnson & Johnson: YoY revenue comparison of Velcade 2013-2015 ($ billions)
Exhibit 96: Johnson & Johnson: YoY revenue comparison of Imbruvica 2014-2015 ($ millions)
Exhibit 97: Key takeaways
Exhibit 98: Pfizer: YoY revenue and growth rate of Sutent 2013-2015 ($ billions)
Exhibit 99: Pfizer: YoY revenue and growth rate of Xalkori 2013-2015 ($ millions)
Exhibit 100: Pfizer: YoY revenue and growth rate of Inlyta 2013-2015 ($ millions)
Exhibit 101: Key takeaways
Exhibit 102: BMS: YoY revenue and growth rate of Erbitux 2013-2015 ($ millions)
Exhibit 103: BMS: YoY revenue and growth rate of Sprycel 2013-2015 ($ billions)
Exhibit 104: Key takeaways



【掲載企業】

F. Hoffmann-La Roche, Novartis, Celgene, Johnson & Johnson, Pfizer, BMS, AbbVie, AbGenomics, ADC Therapeutics, Advantagene, Agensys, Almac Group, Ambrx, Argos Therapeutics, Array BioPharma, Astellas Pharma, AstraZeneca, Bayer, Biogen, Biotech Pharmaceutical, Boehringer Ingelheim, Boston Biomedical, Celldex Therapeutics, Chugai Pharmaceutical, Cold Genesys, CTI BioPharma, Daiichi Sankyo, DNAtrix, Ds-Pharma, Eleison Pharmaceuticals, Eli Lilly, Endo Pharmaceuticals, Formation Biologics, Fortress Biotech, Genmab, GSK, Immatics Biotechnologies, Immunogen, Immunomedics, Intas Pharmaceuticals, Kairos Therapeutics, Kyowa Hakko Kirin, MedImmune, Merck, Mersana Therapeutics, Morphotek, Neovii Biotech, NewLink Genetics, Northwest Biotherapeutics, Novartis, OncoMed Pharmaceuticals, Oxford Biotherapeutics, Peregrine Pharmaceuticals, Polaris Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals, Stemcentrx, Synthon Biopharmaceuticals, TG Therapeutics, XBiotech.

【レポートのキーワード】

固形腫瘍、治療薬、がん、乳癌、NHL、結直腸癌、腎臓がん、医薬品

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

★調査レポート[固形腫瘍治療薬の世界市場2016-2020]販売に関する免責事項
★調査レポート[固形腫瘍治療薬の世界市場2016-2020]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆